IPP Bureau
Health Minister Nadda reviews Ayushman Bharat PMJAY and Ayushman Bharat Digital Mission
By IPP Bureau - July 14, 2024
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
7th India-Japan medical product regulatory symposium held at New Delhi
By IPP Bureau - July 14, 2024
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan
By IPP Bureau - July 14, 2024
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Lupin receives EIR from USFDA for its Dabhasa facility
By IPP Bureau - July 13, 2024
The facility is a part of Lupin Manufacturing Solutions
KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag
By IPP Bureau - July 10, 2024
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
By IPP Bureau - July 10, 2024
The Unit has been issued GMP Certification from ANVISA-Brazil
Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
By IPP Bureau - July 10, 2024
The approved ANDA is therapeutically equivalent to the reference listed drug product
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
By IPP Bureau - July 10, 2024
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Synexa Life Sciences enrolls in My Green Lab Certification Program
By IPP Bureau - July 10, 2024
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening
By IPP Bureau - July 10, 2024
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
By IPP Bureau - July 10, 2024
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Zydus receives tentative approval from USFDA for Diroximel Fumarate DR Capsules
By IPP Bureau - July 10, 2024
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets
By IPP Bureau - July 10, 2024
This product will be manufactured at Lupin’s Pithampur facility in India
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution
By IPP Bureau - July 10, 2024
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
